Company: INTS
Filing Date: 2025-04-24
Form Type: S-1/A
Source: 0001628280-25-019491
Chunk: 24

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-24
Form: S-1/A
Chunk 24
---
 our net proceeds from the sale of 75%, 50%, and 25% of the maximum number of securities offered in this offering would be approximately $1.8 million, $1.1 million, and $0.4 million, respectively, after deducting the estimated Placement Agents’ fees and estimated offering expenses payable by us, and assuming no sale of any Pre-Funded Warrants and assuming no exercise of the Common Warrants. We will only receive additional proceeds from the exercise of the Common Warrants we are selling in this offering if the Common Warrants are exercised for cash. We cannot predict when or if these Common Warrants will be exercised. It is possible that these Common Warrant may expire and may never be exercised.

Each $0.10 increase (decrease) in the assumed public offering price of $1.30 per share of Common Stock and accompanying Common Warrants (which is the last reported sale price of the Common Stock on the Nasdaq Capital Market on April 23, 2025) would increase (decrease) the net proceeds to us from this offering by approximately $0.2 million, assuming the number of securities offered, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated offering expenses payable by us and assuming no sale of any Pre-Funded Warrants and assuming no exercise of the Common Warrants. Each 100,000 share increase (decrease) in the number of securities offered by us in this offering would increase (decrease) the net proceeds to us from this offering by approximately $0.1 million, assuming that the price per share of Common Stock and accompanying Common Warrants for the offering remains at $1.30 (which is the last reported sale price of the Common Stock on the Nasdaq Capital Market on April 23, 2025), and after deducting the estimated offering expenses payable by us and assuming no sale of any Pre-Funded Warrants and assuming no exercise of the Common Warrants included in the securities in the offering. Each 500,000 share increase (decrease) in the number of securities offered by us in this offering would increase (decrease) the net proceeds to us from this offering by approximately $0.6 million, assuming that the price per share of Common Stock and accompanying Common Warrants for the offering remains at $1.30 (which is the last reported sale price of the Common Stock on the Nasdaq Capital Market on April 23, 2025), and after